Methods for treating HCV
View Patent ↗The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise:
Compound 1 having formula of
or a pharmaceutically acceptable salt thereof, and
Compound 4 having formula of
or a pharmaceutically acceptable salt thereof,
wherein Compound 1 or the salt thereof is co-administered with ritonavir.
2. The method of claim 1 , wherein said patient is a treatment-naïve patient.
3. The method of claim 1 , wherein said at least two DAAs further comprise compound 2 having formula of
or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein said at least two DAAs further comprise compound 2 having formula of
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein said patient is infected with HCV genotype 1a.
6. The method of claim 2 , wherein said patient is infected with HCV genotype 1a.
7. The method of claim 3 , wherein said patient is infected with HCV genotype 1a.
8. The method of claim 4 , wherein said patient is infected with HCV genotype 1a.
9. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks.
10. The method of claim 9 , wherein said patient is a treatment-naïve patient.
11. The method of claim 9 , wherein said patient is infected with HCV genotype 1a.
12. The method of claim 10 , wherein said patient is infected with HCV genotype 1a.
13. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of interferon to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment lasts for 12 weeks.
14. The method of claim 13 , wherein said patient is a treatment-naïve patient.
15. The method of claim 13 , wherein said patient is infected with HCV genotype 1a.
16. The method of claim 14 , wherein said patient is infected with HCV genotype 1a.